← All stories
● Covered by 2 sources · 2 reportsMedium impact2 neutral

Isomorphic Labs Secures $5 Billion Series C Funding for AI Drug Discovery

🔄 Updated 4d ago
New to BrevFeed? We gather this story from every outlet covering it into one summary — ranked by real-world impact, not just the latest headline — so you never miss what matters. What is BrevFeed? →

Key points

  • Isomorphic Labs raised $5 billion in Series C funding.
  • Greenoaks and Sequoia Capital co-led the round; Andreessen Horowitz and Alphabet also invested.
  • Funds will support AI drug design and development of new medicines.
  • The company aims to advance drug candidates in oncology and immunology to clinical trials.
  • Isomorphic Labs spun out of Google DeepMind in 2021.

Major Funding Round for AI Drug Discovery

Isomorphic Labs, an artificial intelligence drug discovery startup, announced it has secured $5 billion in a Series C funding round. This significant investment will be used to further the company's efforts in designing and developing new medicines using AI technology.

Investment Details and Participants

The Series C round was co-led by Greenoaks and Sequoia Capital. Additional investors include Andreessen Horowitz and Alphabet, Google's parent company. Existing backers such as Alphabet's venture divisions GV and Capita G, Thrive Capital, MGX, Temasek, and the U.K. Sovereign AI Fund also participated in this round. This funding follows a $2.1 billion Series B round in May.

Advancing AI in Medicine

Isomorphic Labs, founded by Demis Hassabis, who stepped back as CEO of Google DeepMind three-and-a-half months prior, builds an AI drug-design engine. This engine utilizes simulation AI models to explore chemistry and aid in drug design. The company's work builds on DeepMind’s AlphaFold protein-folding AI model.

The new capital will enable Isomorphic Labs to continue developing its drug-design engine and expand into more types of medicine. The company has reported positive preclinical results for its programs in oncology and immunology and aims to advance these drug candidates into clinical trials. Isomorphic Labs has also established deals with pharmaceutical companies like Eli Lilly, Novartis, and Johnson & Johnson.

Company Background

Isomorphic Labs was spun out of Google's DeepMind in 2021. Demis Hassabis has served as CEO of Isomorphic Labs since its inception. Hassabis stated that the company's founding conviction was that biology could be understood and modeled at a fundamental molecular level and accelerated through AI.

✨ This summary was generated by AI from the outlets' reporting listed below. It is not independently verified and may contain errors — check the original sources. How BrevFeed works →

The daily brief

One email each morning: the day's tech stories, clustered across outlets and summarized. No account needed.

One email a day. Unsubscribe in one click, any time.

Today's brief

Spend a few minutes, get the whole day. Every topic's top stories in one hands-free rundown — listen, watch, or read the transcript.

~4 min · 3 stories · Nov 21

▶ Play today's brief Listen on Spotify

New every morning, and the back catalogue is archived by date.

How outlets covered it

Isomorphic Labs, an AI drug-discovery platform spun out of DeepMind, secured $5 billion in Series C funding co-led by Greenoaks and Sequoia Capital. The capital will support the development of its AI drug-design engine and enable the company to advance its drug candidates, which have shown positive preclinical results in oncology and immunology, into clinical trials.

Isomorphic Labs, an AI drug discovery startup founded by Demis Hassabis, secured $5 billion in Series C funding. This investment will support the development of new AI-driven medicines and advance its therapeutic programs toward clinical trials.